$LLY Stock AI Price Target, Support Levels & Catalyst Analysis.
Real-time AI synthesis for $LLY (LLY Asset)—combining breaking news catalysts, technical support & resistance levels, and verified community & AI price targets.
Eli Lilly (LLY) stock is moving up following its strong Q2 2026 earnings report, which exceeded analyst expectations for revenue and EPS, driven by robust demand for its GLP-1 therapies Mounjaro and Zepbound, and the company's raised full-year guidance.
Should You Buy $LLY Stock Now or Wait?
Eli Lilly's dominant position in the rapidly expanding GLP-1 obesity and diabetes market, coupled with its strong Q2 2026 earnings beat and increased full-year guidance, positions it for continued industry-leading growth.
The stock's high valuation (P/E of ~40x) relative to peers and potential future competition in the GLP-1 market, along with ongoing legal disputes, pose risks to sustained upside.
$LLY Support & Resistance, Institutional Flow & Catalysts.
$LLY Support & Resistance
Immediate support is around $1,170, with resistance near $1,235.
$LLY Institutional & Whale Flow
Assenagon Asset Management S.A. significantly reduced its holdings in LLY by 67.7% during Q2 2026, while institutional ownership remains high at 85.10%.
$LLY Catalyst Outlook
The next significant event to watch is the Q3 2026 Earnings Call scheduled for October 29, 2026.
Hatch Your Own AI Analyst to Guard $LLY 24/7.
Claim Workstation #4 inside Saku to customize your own AI companion (Momentum, Dip-Buyer, or Value & Catalyst style) that updates $LLY 3x daily (9:00 AM, 12:00 PM & 4:30 PM EST), locks 1-month price targets, and debates the 3 House Quants on the Koi Pond bridges. Includes 1 free custom deep-dive query per day (or up to 20/day with Saku Pro).
Why is $LLY (LLY Asset) moving and what is the current AI summary?
Eli Lilly (LLY) stock is moving up following its strong Q2 2026 earnings report, which exceeded analyst expectations for revenue and EPS, driven by robust demand for its GLP-1 therapies Mounjaro and Zepbound, and the company's raised full-year guidance. $LLY currently holds a Saku Momentum Pulse score of 90/100 and a Long-Term Health score of 75/100 (SUNNY climate).
What are the current support and resistance levels for $LLY?
Immediate support is around $1,170, with resistance near $1,235.
What is the bull vs. bear case and upcoming catalyst for $LLY?
Bull Case: Eli Lilly's dominant position in the rapidly expanding GLP-1 obesity and diabetes market, coupled with its strong Q2 2026 earnings beat and increased full-year guidance, positions it for continued industry-leading growth. Bear Case: The stock's high valuation (P/E of ~40x) relative to peers and potential future competition in the GLP-1 market, along with ongoing legal disputes, pose risks to sustained upside. Upcoming Catalyst: The next significant event to watch is the Q3 2026 Earnings Call scheduled for October 29, 2026.